



#11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chen et al.

Serial No.: 10/046,526

Group Art Unit No.: 1614

Filed: January 10, 2002

Examiner: Sudhaker B. Patel

For: Substituted Arylamine Derivatives and Methods of Use

Docket No.: A-735A

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provide a copy of each of the listed references for consideration by the Examiner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,
whichever occurs first.

STATEMENT OR FEE

Accompanying this transmittal is:

A ☐ a statement as specified in 37 CFR 1.97(e):

STATEMENT

I, the person(s) signing below state:

EXPRESS MAIL CERTIFICATE

"Express Mail" label number: EV 352489106 US

Date of Deposit: October 9, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sherry St. Andrew

Printed Name

[Signature]
Signature

10/20/2003 FFANREIA 00000057 010519 180.00 DA 01 FC:1806

- ☐ that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).

OR

- ☐ that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).

OR

- B. ☒ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c). (\$180.00).

Applicants request consideration of this information and passage of the application to issue.

FEE PAYMENT

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,



Joseph W. Bullock
Attorney/Agent for Applicant(s)
Registration No.: 37,103

Phone: (805) 447-7966

Date: October 9, 2003

Please send all future correspondence to:

US Patent Operations/ JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799